Study Examines SGLT2 Inhibitor Benefits and Risks in Adults Aged 80 and Above

SGLT2 Inhibitors Latest News

New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD).

About SGLT2 Inhibitors

• SGLT2 (Sodium-Glucose Cotransporter-2) inhibitors are a class of medications primarily used to treat Type 2 diabetes (T2D). 
• T2D, the most common type of diabetes, is a disease that occurs when your blood glucose, also called blood sugar, is too high. 
• SGLT2 Inhibitors manage your blood sugar by helping your kidneys remove extra glucose through your pee. 
• How do SGLT2 inhibitors work?
  • SGLT2 is a protein in your kidneys that reabsorbs glucose. 
  • Typically, when glucose in your blood flows through your kidneys, some glucose goes back into your bloodstream. 
  • SGLT2 inhibitors block that process, so your kidneys don’t reabsorb glucose. 
  • Instead, it comes out in your pee. This means the glucose doesn’t get into your bloodstream and raises your blood sugar. 
• The use of SGLT2 inhibitors goes beyond managing blood sugar. 
  • They also help improve kidney and heart health for people with chronic kidney disease (CKD) or heart failure. 
  • They can slow the progression of kidney disease and reduce the risk of needing dialysis. 
  • SGLT2 inhibitors also lower the risk of heart failure flare-ups. 
• Common SGLT2 inhibitors
  • Dapagliflozin
  • Empagliflozin
  • Canagliflozin
  • Ertugliflozin
• Some of the side effects include:
  • Higher risk of developing genital and urinary tract infections
  • Urinating more frequently
  • Flu like symptoms
  • Nausea
  • Joint pain

News: NM

‹ ›